2 completed, 1 not yet recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Not yet recruiting 1 |
Follow Addpharma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee AD-211-L, AD-211-M, AD-211-H - Osteoarthritis of the Knees | Phase 2 | Not yet recruiting | Addpharma Inc. | 200 | 2026-06-01 | 2026-04-24 |
| A Study to Evaluate the Efficacy and Safety of AD-209 AD-209, AD-209-1A, AD-209-1B - Hypertension, Essential | Phase 2 | Completed | Addpharma Inc. | 221 | 2023-04-05 | 2024-04-05 |
| Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension AD209, Amlodipine low, Amlodipine high - Hypertension,Essential | Phase 2 | Completed | Addpharma Inc. | 176 | 2020-02-25 | 2021-07-21 |
Telmisartan (1)
South Korea (2)
Chang Gyu Park, M.D., Ph.D (1) · ChangGu Park, M.D., Ph.D (1) · Jung Yoon Choi (1)